Nicholas Investment Partners LP Buys New Position in TOCAGEN INC (TOCA)
Nicholas Investment Partners LP bought a new position in TOCAGEN INC (NASDAQ:TOCA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 100,000 shares of the company’s stock, valued at approximately $228,000. Nicholas Investment Partners LP owned about 0.50% of TOCAGEN INC at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Victory Capital Management Inc. bought a new stake in shares of TOCAGEN INC during the second quarter worth approximately $837,000. Alps Advisors Inc. bought a new stake in shares of TOCAGEN INC during the second quarter worth approximately $215,000. New York State Common Retirement Fund bought a new stake in shares of TOCAGEN INC during the second quarter worth approximately $108,000. TIAA CREF Investment Management LLC bought a new stake in shares of TOCAGEN INC during the second quarter worth approximately $273,000. Finally, Teachers Advisors LLC bought a new stake in shares of TOCAGEN INC during the second quarter worth approximately $181,000. 37.87% of the stock is owned by institutional investors.
A number of research firms recently weighed in on TOCA. Zacks Investment Research raised shares of TOCAGEN INC from a “sell” rating to a “hold” rating in a research note on Thursday, September 14th. Stifel Nicolaus reissued a “buy” rating and set a $24.00 price target on shares of TOCAGEN INC in a research note on Tuesday, July 25th.
Shares of TOCAGEN INC (TOCA) opened at 11.86 on Friday. TOCAGEN INC has a 1-year low of $9.68 and a 1-year high of $17.95. The company’s 50 day moving average is $12.39 and its 200-day moving average is $13.40. The company’s market capitalization is $234.93 million.
TOCAGEN INC (NASDAQ:TOCA) last posted its earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.04). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. On average, equities research analysts forecast that TOCAGEN INC will post ($2.51) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Nicholas Investment Partners LP Buys New Position in TOCAGEN INC (TOCA)” was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/22/nicholas-investment-partners-lp-buys-new-position-in-tocagen-inc-toca.html.
TOCAGEN INC Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for TOCAGEN INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TOCAGEN INC and related companies with MarketBeat.com's FREE daily email newsletter.